EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.8.98.2 | Adenocarcinoma |
24189098 |
Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma. |
diagnostic usage ongoing research unassigned |
3 4 0 |
1.8.98.2 | Adenocarcinoma |
32411320 |
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. |
causal interaction diagnostic usage ongoing research therapeutic application |
4 3 2 4 |
1.8.98.2 | Brain Injuries |
25407820 |
Sulfiredoxin-1 Attenuates Oxidative Stress via Nrf2/ARE Pathway and 2-Cys Prdxs After Oxygen-Glucose Deprivation in Astrocytes. |
causal interaction therapeutic application unassigned |
1 2 0 |
1.8.98.2 | Brain Ischemia |
25955519 |
Sulfiredoxin-1 exerts anti-apoptotic and neuroprotective effects against oxidative stress-induced injury in rat cortical astrocytes following exposure to oxygen-glucose deprivation and hydrogen peroxide. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.8.98.2 | Brain Ischemia |
28552673 |
Neuroprotective effects of sulfiredoxin-1 during cerebral ischemia/reperfusion oxidative stress injury in rats. |
causal interaction therapeutic application unassigned |
4 1 0 |
1.8.98.2 | Breast Neoplasms |
21742584 |
Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia. |
diagnostic usage ongoing research therapeutic application unassigned |
3 3 1 0 |
1.8.98.2 | Breast Neoplasms |
22964583 |
Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer. |
causal interaction diagnostic usage ongoing research therapeutic application |
4 4 4 1 |
1.8.98.2 | Breast Neoplasms |
25833832 |
Correction: Genetic Polymorphisms and Protein Expression of NRF2 and Sulfiredoxin Predict Survival Outcomes in Breast Cancer. |
causal interaction diagnostic usage therapeutic application unassigned |
2 3 1 0 |
1.8.98.2 | Carcinogenesis |
21487000 |
Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. |
therapeutic application unassigned |
1 0 |
1.8.98.2 | Carcinogenesis |
23393226 |
Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. |
causal interaction ongoing research unassigned |
1 3 0 |